{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:35:07Z","timestamp":1769114107434,"version":"3.49.0"},"reference-count":16,"publisher":"Japanese Pharmacological Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Folia Pharmacol. Jpn.","Folia Pharmacologica Japonica"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1254\/fpj.21066","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T22:16:17Z","timestamp":1640988977000},"page":"53-61","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)","\u810a\u9ac4\u6027\u7b4b\u840e\u7e2e\u75c7\u907a\u4f1d\u5b50\u6cbb\u7642\u88fd\u54c1\u30aa\u30ca\u30bb\u30e0\u30ce\u30b2\u30f3\u30a2\u30d9\u30d1\u30eb\u30dc\u30d9\u30af\uff08\u30be\u30eb\u30b2\u30f3\u30b9\u30de&lt;sup&gt;\u00ae&lt;\/sup&gt;\uff09\u306e\u85ac\u7406\u5b66\u7684\u7279\u6027\u3068\u81e8\u5e8a\u8a66\u9a13\u6210\u7e3e"],"prefix":"10.1254","volume":"157","author":[{"given":"Ayaka","family":"Atsumi","sequence":"first","affiliation":[{"name":"Medical department of Gene Therapies business Unit, Novartis Pharma K.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Global Drug Development Division, Novartis Pharma K.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tsuchida","sequence":"additional","affiliation":[{"name":"Global Drug Development Division, Novartis Pharma K.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Global Drug Development Division, Novartis Pharma K.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Global Drug Development Division, Novartis Pharma K.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuho","family":"Kawase","sequence":"additional","affiliation":[{"name":"Medical department of Gene Therapies business Unit, Novartis Pharma K.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Medical department of Gene Therapies business Unit, Novartis Pharma K.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"key":"1","unstructured":"1) \u96e3\u75c5\u60c5\u5831\u30bb\u30f3\u30bf\u30fc \u810a\u9ac4\u6027\u7b4b\u840e\u7e2e\u75c7. https:\/\/www.nanbyou.or.jp\/entry\/285. (2021\u5e746\u6708 \u30a2\u30af\u30bb\u30b9)"},{"key":"2","unstructured":"2) \u7b2c3\u56de \u96e3\u75c5\u306b\u95a2\u3059\u308b\u30b2\u30ce\u30e0\u533b\u7642\u306e\u63a8\u9032\u306b\u95a2\u3059\u308b\u691c\u8a0e\u4f1a. https:\/\/mf.jiho.jp\/sites\/default\/files\/mf\/document\/2019\/12\/\u7b2c3\u56de\u96e3\u75c5\u306b\u95a2\u3059\u308b\u30b2\u30ce\u30e0\u533b\u7642\u306e\u63a8\u9032\u306b\u95a2\u3059\u308b\u691c\u8a0e\u4f1a.pdf."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Wirth B. Hum Mutat. 2000;15:228-237.","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sumner CJ, et al. J Clin Invest. 2018;128:3219-3227.","DOI":"10.1172\/JCI121658"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) King NMP, et al. Gene Ther. 2017;24:534-538.","DOI":"10.1038\/gt.2017.32"},{"key":"6","unstructured":"6) \u300c\u30b9\u30d4\u30f3\u30e9\u30b6\u9ac4\u6ce8\u300d\u6dfb\u4ed8\u6587\u66f8 (2019\u5e741\u6708\u6539\u8a02\uff08\u7b2c3\u7248\uff09)."},{"key":"7","unstructured":"7) \u300c\u30be\u30eb\u30b2\u30f3\u30b9\u30de\u70b9\u6ef4\u9759\u6ce8\u300d\u6dfb\u4ed8\u6587\u66f8 (2021\u5e7413\u6708\u6539\u8a02\uff08\u7b2c3\u7248\uff09)."},{"key":"8","unstructured":"8) \u539a\u751f\u52b4\u50cd\u7701. \u907a\u4f1d\u5b50\u6cbb\u7642\u7b49\u81e8\u5e8a\u7814\u7a76\u306b\u95a2\u3059\u308b\u6307\u91dd. https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka\/150812_rinrisisin.pdf."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Dunbar CE, et al. Science. 2018;80:359.","DOI":"10.1126\/science.aan4672"},{"key":"10","unstructured":"10) \u30be\u30eb\u30b2\u30f3\u30b9\u30de \u5be9\u67fb\u5831\u544a\u66f8. \u533b\u85ac\u54c1\u533b\u7642\u6a5f\u5668\u7dcf\u5408\u6a5f\u69cb (2020). https:\/\/www.pmda.go.jp\/regenerative_medicines\/2020\/R20200407001\/300242000_30200FZX00001000_A100_2.pdf."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Mendell JR, et al. N Engl J Med. 2017;377:1713-1722.","DOI":"10.1056\/NEJMoa1706198"},{"key":"12","unstructured":"12) San Antonio NB. Bayley-III Technical Manual., TX: Harcourt Assessment."},{"key":"13","unstructured":"13) Matthew M, et al. Long-Term Follow-Up (LTFU) of Onasemnogene Abeparvovec gene therapy in spinal muscular atrophy (SMA). MDA Clinical &amp; Scientific Conference 2021, Poster No.63, (2021)."},{"key":"14","unstructured":"14) Strauss KA, et al. Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy: SPR1NT Study Update in Children with Two Copies of SMN2. MDA Clinical &amp; Scientific Conference, Poster No. 67, (2021)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Strauss KA, et al. Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy: SPR1NT Study Update in Children with Three Copies of SMN2. MDA Clinical &amp; Scientific Conference, Poster No. 68, (2021)","DOI":"10.1212\/WNL.96.15_supplement.4190"},{"key":"16","unstructured":"16) \u30be\u30eb\u30b2\u30f3\u30b9\u30de\u70b9\u6ef4\u9759\u6ce8 \u9069\u6b63\u4f7f\u7528\u6307\u91dd. \u4e00\u822c\u793e\u56e3\u6cd5\u4eba \u65e5\u672c\u5c0f\u5150\u795e\u7d4c\u5b66\u4f1a, 2021\u5e743\u670830\u65e5."}],"container-title":["Folia Pharmacologica Japonica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fpj\/157\/1\/157_21066\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T12:52:05Z","timestamp":1726404725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fpj\/157\/1\/157_21066\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1254\/fpj.21066","relation":{},"ISSN":["0015-5691","1347-8397"],"issn-type":[{"value":"0015-5691","type":"print"},{"value":"1347-8397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"21066"}}